Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2003-11-21
2010-10-12
Minnifield, N. M (Department: 1645)
Chemistry: molecular biology and microbiology
Vector, per se
Reexamination Certificate
active
07811813
ABSTRACT:
This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-protein(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-protein(s), -polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.
REFERENCES:
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6225292 (2001-05-01), Raz et al.
patent: 6610661 (2003-08-01), Carson et al.
patent: 6949520 (2005-09-01), Hartmann et al.
patent: 7544669 (2009-06-01), Fontoura et al.
patent: 7579328 (2009-08-01), Steinman et al.
patent: 7585843 (2009-09-01), Garren et al.
patent: 7704970 (2010-04-01), Steinman et al.
patent: 2002/0164341 (2002-11-01), Davis et al.
patent: 2003/0181406 (2003-09-01), Schetter et al.
patent: 2005/0002953 (2005-01-01), Herold
patent: 2009/0208481 (2009-08-01), Steinman et al.
patent: 2009/0264515 (2009-10-01), Fontoura et al.
patent: 2009/0281170 (2009-11-01), Fontoura et al.
patent: 2010/0048679 (2010-02-01), Garren et al.
patent: 2010/0074907 (2010-03-01), Mi et al.
patent: WO 01/51626 (2001-07-01), None
Sugiyama et al, J. Immunology, 2005, 174:2273-2279.
Puig et al, Nucleic Acids Research, 2006, 34/22:6488-6495.
Dalpke et al, Immunology, 2002, 106:102-112.
Ballas et al, J. Immunology, 2001, 167:4878-4886.
Krieg et al, Nature, 2002, 374:546-549 abstract only.
Lipford et al, Immunology, 2000, 101:46-52.
Shen et al, Antisense & Nucleic Acid Drug Development, 2002, 12:155-164.
Obermeier et al, Eur. J. Immunol., 2002, 32:2084-2092.
Wooldridge et al, Blood, 1997, 89/8:2994-2998.
Whitmore et al, Cancer Immunol. Immunother., 2001, 50:503-514.
Lee et al, J. Immunol., 2000, 165:3631-3639.
Mempl et al, Immunology Letters, 2003, 89:47-57.
Zhang et al, J. Neuroimmunology, 2005, 161:68-77.
Ho et al, J. Immunology, 2003, 171:4920-4926.
Van Uden, Dissertation Abstracts International, 2001, 62/5B:2248 abstract only.
Boccaccio et al, International Immunology, 1999, 11/2:289-296.
Oxienius et al, I. Virology, 1999, 73/5:4120-4126.
Lobell et al, J. Immunology, 1999, 163:4754-4762.
Krieg et al, PNAS, 1998, 95:12631-12636.
Krieg, Handbook of Experimental Pharmacology, 1998, 131:243-262.
Ho et al, Autoimmunity, Dec. 2006, 39/8:675-682.
Bar-Or et al, Arch. Neurol., 2007, 64/10:1407-1415.
Garren et al, Ann. Neurol., 2008, 63:611-620.
Robinson et al, Nature Biotechnology, Sep. 2003, 21/9:1033-1039.
Solvason et al, I. Immunol., 2008, 181:8298-8307.
Ho et al., “An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems”,J. Immunology, 2003, pp. 4920-4926, vol. 171.
Klinman et al., “CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon y”,Proc Nat. Acad. U.S.A., 1996, pp. 2879-2883, vol. 93.
Krieg et al., “CpG motifs in bacterial DNA trigger direct B-Cell activation”,Nature, 1995, pp. 546-549, vol. 374.
Martin-Orozco et al., “Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences”,Int. Immunol., 1999, pp. 1111-1118, vol. 11(7).
Sparwasser et al., “Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells”,Eur. J. Immunol., 1998, pp. 2045-2054, vol. 28.
Stacey et al., “Immunostimulatory DNA as an adjuvant in vaccination againstLeishmania major”, Infection and Immunity, 1999, pp. 3719-3726, vol. 67(8).
Yi et al., “Rapid Immune Activation by CpG Motifs in Bacterial DNA”,J. Immunol., 1996, pp. 5394-5402, vol. 157.
Zeuner et al., “Reduction of CpG-Induced Arthritis by Suppressive Oligodeoxynucleotides”Arthritis and Rheumatism, 2002, pp. 2219-2224, vol. 46(8).
Lenert, Petar et al.; “CpG Stimulation of Promary Mouse B Cells is Blocked by Inhibitory Oligodeoxyribonucleotides at a Site Proximal to NF-κB Activation”; 2001,Antisense&Nuclecic Acid Drug Development, vol. 11, pp. 247-256.
Yew, Nelson S. et al.; “Reduced Inflammatory Response to Plasmid DNA Vectors by Elimination and Inhibition of Immunostimulatory CpG Motifs”; 2000,Molecular Therapy, vol. 1, No. 3, pp. 255-262.
Invitrogen: pVAX1 (Catalog No. V260-20) version B 010124/25-0256, 1998, 15 pages.
Garren Hideki
Ho Peggy P.
Steinman Lawrence
Bayhill Therapeutics, Inc.
Minnifield N. M
The Board of Trustees of the Leland Stanford Junior University
Townsend and Townsend / and Crew LLP
LandOfFree
Methods and immune modulatory nucleic acid compositions for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and immune modulatory nucleic acid compositions for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and immune modulatory nucleic acid compositions for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172106